insulin secretagogue — Competitive Intelligence Brief

insulin secretagogue (insulin secretagogue) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin secretagogue. Area: Diabetes.

phase 3 Insulin secretagogue ATP-sensitive potassium channels Diabetes Small molecule

Target snapshot

insulin secretagogue (insulin secretagogue) — Sanofi. Stimulates the release of insulin from the pancreas.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
insulin secretagogue TARGET	insulin secretagogue	Sanofi	phase 3	Insulin secretagogue	ATP-sensitive potassium channels
Sevoflurane (Preconditioning)	Sevoflurane (Preconditioning)	University of Zurich	marketed	Volatile anesthetic with cardioprotective preconditioning properties	Mitochondrial ATP-sensitive potassium channels (mitoKATP); protein kinase C; endothelial nitric oxide synthase
Minoxidil lotion 1%	Minoxidil lotion 1%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels
metformin, glyburide and glargine	metformin, glyburide and glargine	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin)	Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine)
Minoxidil lotion 2%	Minoxidil lotion 2%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels (KATP); exact follicle-specific target unclear
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Topical Minoxidil（5%） to the scalp.	Topical Minoxidil（5%） to the scalp.	Southern Medical University, China	marketed	Potassium channel opener / topical vasodilator	ATP-sensitive potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin secretagogue class)

1. Creative Peptides Sweden Inc. · 1 drug in this class
2. Sanofi · 1 drug in this class